Shares of Summit Therapeutics Inc. (NASDAQ:SMMT – Get Free Report) fell 5.5% during mid-day trading on Friday . The stock traded as low as $4.29 and last traded at $4.30. 1,004,878 shares traded hands during mid-day trading, a decline of 53% from the average session volume of 2,128,692 shares. The stock had previously closed at $4.55.
Analysts Set New Price Targets
Separately, StockNews.com began coverage on Summit Therapeutics in a research report on Thursday, October 5th. They issued a “hold” rating on the stock.
Summit Therapeutics Stock Performance
Summit Therapeutics (NASDAQ:SMMT – Get Free Report) last announced its quarterly earnings data on Tuesday, November 7th. The company reported ($0.03) earnings per share for the quarter. The business had revenue of $0.27 million during the quarter.
Insider Buying and Selling at Summit Therapeutics
In other news, CFO Ankur Dhingra purchased 20,400 shares of the firm’s stock in a transaction dated Wednesday, December 13th. The shares were acquired at an average price of $2.17 per share, with a total value of $44,268.00. Following the purchase, the chief financial officer now directly owns 254,958 shares of the company’s stock, valued at $553,258.86. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. 83.70% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On Summit Therapeutics
A number of institutional investors and hedge funds have recently bought and sold shares of SMMT. Polar Capital Holdings Plc raised its holdings in Summit Therapeutics by 2.5% in the 1st quarter. Polar Capital Holdings Plc now owns 6,272,509 shares of the company’s stock valued at $15,368,000 after acquiring an additional 154,598 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in shares of Summit Therapeutics during the 2nd quarter worth $49,000. Millennium Management LLC acquired a new stake in shares of Summit Therapeutics during the 2nd quarter worth $457,000. BlackRock Inc. increased its holdings in shares of Summit Therapeutics by 39.3% during the 3rd quarter. BlackRock Inc. now owns 421,086 shares of the company’s stock worth $500,000 after buying an additional 118,878 shares during the last quarter. Finally, Marshall Wace LLP acquired a new stake in shares of Summit Therapeutics during the 3rd quarter worth $167,000. Hedge funds and other institutional investors own 5.01% of the company’s stock.
Summit Therapeutics Company Profile
Summit Therapeutics Inc, a biopharmaceutical company, research and develops primarily oncology therapies in the United States, and the United Kingdom. The company's product pipeline includes SMT-738, a novel class of precision antibiotics for treatment which is in preclinical stage for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections.
- Five stocks we like better than Summit Therapeutics
- How to Invest in Insurance Companies: A Guide
- The next meme stock: 6 tickers leading a meme stock revival
- How to Calculate Stock Profit
- 8 best meme stocks to buy now
- 3 Warren Buffett Stocks to Buy Now
- 3 best meme ETFs to buy now
Receive News & Ratings for Summit Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.